Please assess the completion status of the following clinical trial:

Trial Title: Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) in first or subsequent remission~ * ALL or AML in relapse or primary refractory ALL or AML with a circulating blast count ≤ 10,000/mm\^3~ * Refractory anemia with excess blasts (RAEB) (RAEB-1 or RAEB-2) if the patient has received induction chemotherapy within the past 60 days~* Appropriate candidate for allogeneic hematopoietic stem cell transplantation (HSCT)~* No CNS involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiotherapy~PATIENT CHARACTERISTICS:~* Age 14-55~* Creatinine \< 1.5 mg/dL~* Cardiac ejection fraction \> 45%~* DLCO corrected \> 60% of predicted~* Total bilirubin \< 2 times upper limit of normal (ULN) (unless attributed to Gilbert syndrome)~* AST and ALT \< 2 times ULN~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after transplantation~* HIV negative~* No co-existing disease (other than leukemia or RAEB) that would limit life expectancy to \< 3 months~* No uncontrolled infection that, in the opinion of the consulting infectious disease physician, would contraindicate myeloablative HSCT~* No other medical condition that would contraindicate HSCT~* No known hypersensitivity to tacrolimus~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior HSCT~* No concurrent participation in other experimental studies for the prevention of graft-vs-host disease~DONOR CHARACTERISTICS:~* Genotypic or phenotypic HLA-identical related donor~* Able to donate peripheral blood stem cells~* Age \> 14 years~* Applicable to male patients only: No female donors who have previously given birth to a male child or have had a pregnancy beyond the first trimester miscarriage or termination of pregnancy or nursing~* No donors who have received blood transfusions~* No CD45 Mutation with aberrant CD45RA isoform expression

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD.

Based on this trial design, predict the completion outcome and termination type (if applicable).